Clinical Trial

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

Study acronym: SEPVADIS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-03-11; most recent amendment 2025-10-13.
Status change: Not Yet Recruiting → Recruiting 2021-09-21
Trial Details
NCT Number NCT04797286
Lead Sponsor Johns Hopkins University
Collaborators: Louisiana State University Health Sciences Center in New Orleans, United States Department of Defense
Conditions Scleroderma, Mildly Elevated Pulmonary Pressures
Enrollment 30 participants
Start Date 2021-09-20
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-15